EVOLUS, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
EVOLUS, INC. (EOLS) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $67.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-25.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2020-02-25
- EVOLUS, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2018-03-31 was $67.00M.
- EVOLUS, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $67.00M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|
| 2018-12-31 | $67.00M 10-K · filed 2020-02-25 | |
| 2018-03-31 | $67.00M 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |